Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Xencor Inc (NASDAQ:XNCR)

22.35
Delayed Data
As of Dec 08
 +0.09 / +0.40%
Today’s Change
18.55
Today|||52-Week Range
28.64
-15.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.0B

Company Description

Xencor, Inc. is a clinical stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases, asthma & allergic diseases and cancer. Its clinical sate XmAb technology is used for the treatment of IgG4-related disease; systemic lupus erythematosus; asthma & allergic diseases; acute myeloid leukemia; B-cell malignancies; and neuroendocrine tumors. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Contact Information

Xencor, Inc.
111 West Lemon Avenue
Monrovia California 91016
P:(626) 305-5900
Investor Relations:
(626) 737-8013

Employees

Shareholders

Mutual fund holders55.91%
Other institutional39.20%
Individual stakeholders39.07%

Top Executives

Bassil I. DahiyatPresident, Chief Executive Officer & Director
John J. KuchSecretary & Vice President-Finance
John R. DesjarlaisChief Scientific Officer & Senior VP-Research
Paul A. FosterChief Medical Officer & Senior Vice President
Edgardo BaracchiniChief Business Officer